The antiproliferative potential of C1 against human cervical carcinoma (HeLa), highly metastatic breast adenocarcinoma (MDA-MB-231), human colorectal carcinoma (HCT 116 p53++ and HCT 116 p53−−) and multidrug resistant mouse mammary tumour (EMT6/AR1) cells was evaluated (Figure 10A). This evidence concerns the gene TP53 and cervical carcinoma.